| 1 |
Pellagatti A, Jadersten M, Forsblom AM, et al. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly delelted region in 5q-syndrome patients [J]. Proc Natl Acad Sci USA, 2007, 104(27): 11406-11411.
|
| 2 |
Mallo M, Cervera J, Schanz J, et al. Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q [J]. Leukemia, 2011, 25(1): 110-120.
|
| 3 |
Evers C, Beier M, Poelitz A, et al. Molecular definition of chromosome arm 5q deletion end points and detection of hidden aberrations in patients with myelodysplastic syndromes and isolated del(5q) using oligonucleotide array CGH [J]. Genes Chromosomes Cancer, 2007, 46(12): 1119-1128.
|
| 4 |
Giagounidis AA, Germing U, Strupp C, et al. Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup [J]. Ann Hematol, 2005, 84(9): 569-571.
|
| 5 |
Venkataswamy E, Nargund AR, Prabhudesai S, et al. An uncommon case of an adult with del(5)(q) in acute lymphoblastic leukemia. [J].Indian J Hum Genet, 2012, 18(3): 349-351.
|
| 6 |
Ebert BL, Pretz J, Bosco J, et a1. Identification of RPS14 as a 5q-syndrome gene by RNA interference screen [J]. Nature, 2008, 451(7176): 335-339.
|
| 7 |
Danilova N, Sakamoto KM, Lin S. Ribosomal protein S19 deficiency in zebrafish leads to developmental abnormalities and defective erythropoiesis through activation of p53 protein family [J]. Blood, 2008, 112(13): 5228-5237．
|
| 8 |
Jädersten M, Hellström-Lindberg E. New clues to the molecular pathogenesis of myelodysplastic syndromes? [J]. Exp Cell Res, 2010, 316(8): 1390-1396．
|
| 9 |
Oliva EN, Cuzzola M, Nobile F, et al. Changes in RPS14 expression levels during lenalidomide treatment in low and Intermediate -risk myelodysplastic syndromes with chomosome 5q deletion [J]. Eur J Haematol, 2010, 85(3): 231-235．
|
| 10 |
Abouyahya I, Alhan C, Western TM, et al. Treatment with lenalidomide in myelodysplastic syndromes with deletion 5q: results from the Dutch named patient program [J]. Leuk Lymphoma, 2013, 54(4): 874-877.
|
| 11 |
Starczynowski DT, Kuchenbauer F, Argiropoulos B, et a1. Identification of miR-145 and miR-146a as mediators of the 5q-syndrome phenotype [J]. Nat Med, 2010, 16(1): 49-58．
|
| 12 |
Curtale G, Citarela F, Carissimi C, et a1. An emerglng player in the adaptive immune response: microRNA-146a is a modulator of IL-2 expression and AICD in T lymphoeytes [J]. Blood, 2010, 115(2): 265-273.
|
| 13 |
Dostalova Merkerova M, Krejcik Z, Votavova H, et a1. Distinctive microRNA expression profiles in CD34+ bone marrow cells from patients with myelodysplastic syndrome [J]. Eur J Hum Genet, 2011, 19(3): 313-319.
|
| 14 |
Hussein K, Theophile K, Btische G, et al. Significant inverse correlation of microRNA-150/MYB and microRNA-222/P27 in myelodysplastic syndrome [J]. Leuk Res, 2010, 34(3): 328-334.
|
| 15 |
Gohring G, Giagounidis A, Busche G, et al. Patients with del(5q)MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression [J]. Ann Hematol, 2010, 89(4): 365-374.
|
| 16 |
Tehranchi R, Woll PS, Anderson K, et al. Persistent malignant stem cells in del(5q) myelodysplasia in remission [J]. N Engl J Med, 2010, 363(11): 1025-1037．
|
| 17 |
Wei S, Chen X, Rocha K, et al. A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide [J]. Proc Natl Acad Sci U S A, 2009, 106(31): 12974-12979.
|
| 18 |
List A, Kurtin S, Roe DJ, et al. Eficacy of lenalidomide in the myelodysplastie syndromes [J]. N Engl J Med, 2005, 352(6): 549-557.
|
| 19 |
List A, Dewaid G, Bennett J, et al. Lenalidomide in the myelody-splastic syndrome with chromosome 5qdeletion [J]. N Engl J Med, 2006, 355: 1456-1465.
|
| 20 |
Tehranchi R, Woll PS, Anderson K, et al. Persistent malignant stem cells in del(5q) myelodysplasia in remission [J]. N Engl J Med, 2010, 363(11): 1025-1137.
|
| 21 |
Jabbour E, Issa JP, Garcia-Manero G, et al. Evolution of decitabine development: accomplishments, ongoing investigations. and future strategies [J]. Cancer, 2008, 112(11): 2341-2351.
|
| 22 |
Negrotto S, Ng KP, Jankowska AM, et al. CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal-hematopoietic precursors [J]. Leukemia, 2012, 26(2): 244-254.
|
| 23 |
Huang J, Hong M, Zhu Y, et al. Multicenter, Rndomized, Open-Label, Phase III Trial of Decitbine Versus patientchoice, with physician advice, of either supportive care or low-dose cytrbine for the treatment of older patients with newly diagnosed acute myeloid leukemi [J]. J Clin Oncol, 2012, 30(21): 2670-2677.
|
| 24 |
Thomas XG, Arthur C, Delaunay J, et al. A post hoc sensitivity analysis of survival probabilities in a multinational phaseⅢ trial of decitabine in older patients with newly iagnosed acute myeloid leukemia [J]. Clin Lymphoma Myeloma Leuk, 2014, 11(1): 68-71.
|
| 25 |
蔡成森，孙爱宁，仇惠英, 等. 地西他滨单药及联合AAG方案治疗初治急性髓系白血病的临床观察 [J/CD]. 中华临床医师杂志(电子版), 2012, 6(19): 6092-6094.
|
| 26 |
高苏，胡晓慧，仇惠英, 等. 地西他滨单药五天方案治疗复杂核型骨髓增生异常综合征和急性髓系白血病疗效观察 [J]. 中华血液学杂志, 2013, 34(6): 542-543.
|